CNBX Pharmaceuticals Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q4 2013 to Q4 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
CNBX Pharmaceuticals Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q4 2013 to Q4 2024.
- CNBX Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending November 30, 2024 was -$34.4K, a 80.8% increase year-over-year.
- CNBX Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending November 30, 2024 was -$551K, a 84.1% increase year-over-year.
- CNBX Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$695K, a 81.3% increase from 2023.
- CNBX Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$3.71M, a 15.5% increase from 2022.
- CNBX Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$4.39M, a 88.9% decline from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)